Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Evaluating bone marrow sample quality derived using a non-redirection versus a traditional bone marrow aspiration and biopsy technique

Isabella Gau, Lydia Benitez, Rana Chouaib et al. Nov 03, 2025 pp. 2649-2649 10.1182/blood-2025-2649

Abstract Background:The traditional bone marrow aspiration and biopsy technique involves the insertion of the biopsy needle once to obtain a...

In-hospital stroke, myocardial infarction, and venous thrombosis in immune thrombocytopenia: Incidence, risk factors, and outcomes from a national cohort

Kunal Sharma, Lakshmi Kattamuri, Abhizith Deoker et al. Nov 03, 2025 pp. 4473-4473 10.1182/blood-2025-4473

Abstract Background: Immune Thrombocytopenia (ITP) is paradoxically associated with an increased risk of thrombotic even...

Daratumumab plus cyclophosphamide, bortezomib and dexamethasone in newly diagnosed patients with light-chain amyloidosis: Interim analysis from an Italian, multicenter, retro-prospective real-world experience

Angela Maria Quinto, Felice Clemente, Elisabetta Antonioli et al. Nov 03, 2025 pp. 828-828 10.1182/blood-2025-828

Abstract Systemic immunoglobulin light-chain (AL) amyloidosis is a rare plasma cell disorder caused by a clone producing unstable misfolded...

Evaluating gvhd outcomes after chemotherapy-only conditioning in nicotinamide-expanded umbilical cord blood (omidubicel) transplantation: A retrospective cohort study

Alexander O'Hara, Abhilasha Kumar, Dawn Marie Stull et al. Nov 03, 2025 pp. 4223-4223 10.1182/blood-2025-4223

Abstract INTRO: Omidubicel (Omi) is an ex vivo expanded hematopoietic progenitor cell product derived from a single umbilical cord blood (UC...

Dara-RVD in newly diagnosed multiple myeloma: Real-world clinical practice

Anastasia Semenova, Stanislav Kamyshanov, Arman Arakelyan et al. Nov 03, 2025 pp. 7591-7591 10.1182/blood-2025-7591

Abstract Background: Despite significant advances in therapy, multiple myeloma (MM) remains an incurable disease thus far. Patients with hig...

Epcoritamab combinations demonstrate promising efficacy in patients (pts) with Richter transformation (RT): First results from arms 2B (epcor + lenalidomide [LEN]) and 2C (epcor + R-CHOP) of the phase 1b/2 EPCORE CLL-1 trial

Philip Thompson, Tamar Tadmor, Hans Herluf Bentzen et al. Nov 03, 2025 pp. 1015-1015 10.1182/blood-2025-1015

Abstract Introduction: RT is an aggressive transformation of chronic lymphocytic leukemia (CLL), most often into diffuse large B-cell lympho...

Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and adverse outcomes in Relapsed/Refractory multiple myeloma (RRMM)

Masooma Rana, Alexandria Jensen, Arash Velayati et al. Nov 03, 2025 pp. 4586-4586 10.1182/blood-2025-4586

Abstract Background: Bridging therapy (BT) is critical for delivering chimeric antigen receptor T (CAR-T) therapy in patients with RRMM as m...

Transferrin receptor 2 (Tfr2) is necessary for hepcidin induction in mice with hepatocyte-specific transferrin receptor 1 (Tfr1) deficiency

Sofiya Tsyplenkova, Siqi Liu, Edouard Charlebois et al. Nov 03, 2025 pp. 4679-4679 10.1182/blood-2025-4679

Abstract In hepatocytes, transferrin receptor 1 (Tfr1) does not have a major role in iron acquisition but rather controls signaling to the i...

LILRB4 drives proinflammatory cytokine secretion in multiple myeloma to promote the immune-cell dysfunction via the generation of myeloid-derived suppressive cells

Lanting Liu, Hao Sun, Yijie Wang et al. Nov 03, 2025 pp. 5695-5695 10.1182/blood-2025-5695

Abstract Recent advancements in the treatment of multiple myeloma (MM), including immunomodulatory agents, monoclonal antibodies, and T cell...

Clinical characteristics, treatment patterns, clinical outcomes and resource utilization in patients with chronic lymphocytic leukaemia (CLL): CREEK-Latin America subgroup analysis

Miguel Pavlovsky, Milton Lombana, Macarena Roa et al. Nov 03, 2025 pp. 4500-4500 10.1182/blood-2025-4500

Abstract Introduction: There is an unmet need to understand how novel therapies translate into real-world clinical practice for CLL, particu...

Targeting mitochondrial metabolism to suppress neutrophil overactivation in sepsis: Therapeutic potential of the mitochondrial uncoupler BAM15

Kritsanawan Sae-khow, Awirut Charoensappakit, Patinya Maneesow et al. Nov 03, 2025 pp. 2981-2981 10.1182/blood-2025-2981

Abstract Background: Understanding the immunometabolic reprogramming that occurs during sepsis is crucial for designing future therapeutics...

Endothelial SRSF1 regulates hematopoietic stem cell function in the bone marrow microenvironment

Kruti Bosmia, Agatha Winiarski, Cody Carter et al. Nov 03, 2025 pp. 4966-4966 10.1182/blood-2025-4966

Abstract The bone marrow (BM) microenvironment is a dynamic cellular network composed of endothelial cells (ECs) and EC-associated perivascu...

Rising sepsis-related mortality in aplastic anemia: A u.S. population-based analysis of temporal trends, disparities, and forecasts through 2030

Haseeb Tareen, Allah Dad, Erum Siddiqui et al. Nov 03, 2025 pp. 6715-6715 10.1182/blood-2025-6715

Abstract Background: Patients with aplastic anemia (AA) are at increased risk of sepsis-related mortality due to underlying immunosuppressio...

Treatments and outcomes of adult patients with TP53-mutated acute myeloid leukemia (AML) in the real-life –Report of the prospective french observational ALFA-PPP study.

Jean-Baptiste Micol, Raphaël Itzykson, Laure Farnault et al. Nov 03, 2025 pp. 6386-6386 10.1182/blood-2025-6386

Abstract Introduction The prognosis of AML harboring TP53 mutations remains exceptionally poor. Clinical trials specifically designed for TP...

Association of race and ethnicity and incidence and severity of hyperglycemia and clinically-treated hypertension during induction therapy for pediatric acute lymphoblastic leukemia

Jason Stevenson, Anjali Khanna, Ashleigh Hawk et al. Nov 03, 2025 pp. 2736-2736 10.1182/blood-2025-2736

Abstract Background: Anti-cancer therapies used to treat pediatric acute lymphoblastic leukemia (ALL) achieve high cure rates but can cause...

Outcomes of diffuse large B-cell lymphoma and high-grade B-cell lymphoma in elderly patients aged ≥ 80 years-old treated in first line therapy: An analysis of the bra-DLBCL multicenter, real-world registry, retrospective study

Carolina Feres, Guilherme Perini, Larissa Teixeira et al. Nov 03, 2025 pp. 8070-8070 10.1182/blood-2025-8070

Abstract Introduction Only a few studies have been conducted in elderly patients with diffuse large B-cell lymphoma (DLB...

Scoping review of current practices and recommendations on fertility preservation in sickle cell disease

Andrienne Mckenzie, Oluwaseun 'kemi Olaiya, Cheryl Mensah Nov 03, 2025 pp. 7887-7887 10.1182/blood-2025-7887

Abstract Introduction: Sickle cell disease and its treatments, mainly hydroxyurea and transformative therapies, are associated with male and...

Age-ing study: A prospective evaluation of geriatric, patient-reported and frailty assessments to predict outcomes in older adults with acute myeloid leukemia

Catherine Lai, Thomas Greenwood, E. Paul Wileyto et al. Nov 03, 2025 pp. 2843-2843 10.1182/blood-2025-2843

Abstract Background: Acute myeloid leukemia (AML) primarily affects older adults. Despite the survival benefit of intens...

FLT3-ITD drives poor prognosis in NPM1 mutated AML via BCAT1-dependent epigenetic regulation

Kainan Zhang, Xiaohang Ma, Xiaoxuan Lu et al. Nov 03, 2025 pp. 5003-5003 10.1182/blood-2025-5003

Abstract NPM1 mutations (NPM1mut) are detected in approximately 30% of adult AML cases. Patients with coexisting NPM1 mutations and FLT3-ITD...

Enhanced CD34+ cell mobilizations, collections, and comparable safety profile with fixed-dose versus weight-based plerixafor dosing in patients with sickle cell disease receiving autologous CD34+ base-edited hematopoietic stem cells (BEAM-101) in the ongoing BEACON study

Haydar Frangoul, Bahru Habtemariam, Arthur Lo et al. Nov 03, 2025 pp. 1049-1049 10.1182/blood-2025-1049

Abstract Introduction Autologous transplantation with genetically modified hematopoietic stem and progenitor cells (HSPCs) for sickle cell d...

Unsupervised proteomic and metabolomic longitudinal serum profiling of anti-CD19 CAR-T cell therapy recipients reveals clinically distinct groups

Jaromir Tomasik, Kannathasan Thetchinamoorthy, Diana Wierzbicka et al. Nov 03, 2025 pp. 5926-5926 10.1182/blood-2025-5926

Abstract Introduction: Despite the clinical success of Chimeric Antigen Receptor (CAR)-T cell therapy, it still faces multiple challenges, s...

Evaluating the impact of AI tools on diagnostics and management of hematologic malignancies (2020–2025): A systematic review

Filip Sadurski, Mousa Thalji, Rohit Sharma Nov 03, 2025 pp. 7871-7871 10.1182/blood-2025-7871

Abstract Background: In recent years there has been rapid growth in artificial intelligence (AI) applications for hematologic malignancies....

Rapid normalization of platelet counts in patients with refractory thrombocytopenia associated with systemic lupus erythematosus (SLE) following treatment with allogeneic dual-target CD19/BCMA CAR T-cell therapy (QT-019B)

Mengtao Li, Runxia Gu, mucong Li et al. Nov 03, 2025 pp. 3031-3031 10.1182/blood-2025-3031

Abstract Background Systemic lupus erythematosus with immune thrombocytopenia (SLE-ITP) is a severe condition associated with poor prognosis...

Thyroid hormones enhance the responsiveness of T-cell lymphomas to romidepsin

María Debernardi, Lucero Alvarado, Helena Sterle et al. Nov 03, 2025 pp. 3554-3554 10.1182/blood-2025-3554

Abstract T-cell lymphomas (TCL) are aggressive and clinically heterogeneous malignancies originating from mature or immature T cells. Standa...

Computed tomography quantification of body adiposity and induction outcomes in patients with newly diagnosed acute lymphoblastic leukemia

Jose Tinajero, Hoda Pourhassan, Chandana Lall et al. Nov 03, 2025 pp. 6829-6829 10.1182/blood-2025-6829

Abstract Background Obesity is encountered in up to 40% of children and adolescents who initiate acute lymphoblastic leu...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page